What's Next for FDA's AI-Enabled Medical Device Policy?

The FDA's discussions about AI-enabled medical devices has moved beyond whether a product performs well before authorization. The agency is also examining how developers can demonstrate that devices remain reliable as patients, clinical workflows, data inputs, and underlying technology change.

Its latest public consultation helps explain where that discussion stands, and what prudent companies will prepare for next.

FDA's Evolving Approach to Generative AI Medical Devices

The FDA's August discussion paper, Considerations for the Regulation of Generative AI-Enabled Medical Devices, addresses risk assessment, premarket evaluation, postmarket monitoring, and questions involving foundation models and agentic AI. It likewise does not establish new regulatory expectations. Instead, it broadens the policy conversation.

Alongside monitoring performance, the FDA is exploring how to evaluate technologies capable of producing variable outputs and operating with different degrees of autonomy. Its August announcement described potential approaches involving competency assessment, device benchmarking, clinical confirmation, and monitoring proportionate to risk.

What Companies Can Do Now

Prudent companies can use this period to build a more specific account of their real-world monitoring needs. That means identifying which performance measures matter, what data is available after deployment, and what would trigger further investigation or intervention. Further, companies should identify which questions are relevant to their technology and where they can contribute concrete evidence about testing, oversight, and deployment.

From a government affairs perspective, the next step is to turn that experience into a focused policy agenda: clear priorities, documented implementation challenges, and practical recommendations that connect patient protection with workable development and monitoring approaches.

The Well Group is perfectly positioned to help companies track FDA developments, assess public stakeholder positions, develop policy priorities, and prepare for future engagement alongside their technical and regulatory advisers.